 Relative prevalence risk factors HTLV-I HTLV-II infection US blood donors clinical significance human T-cell lymphotropic virus type II HTLV-II infection HTLV-I unknown major association HTLV-II seropositivity intravenous drug abuse Screening blood donors HTLV-I North America retrovirus HTLV-II seroepidemiology risk factors HTLV II blood volunteer donors separate US urban centres antibodies HTLV-I/II Confirmed HTLV-I/II seropositive donors DNA amplification type type II interviews possible risk factors HTLV seroprevalence times vs DNA amplification HTLV-I/II seropositive donors HTLV-II infection HTLV-I samples uninformative Interviews donors whereas HTLV-I donor origin endemic regions major risk factor HTLV-II infection intravenous drug use high rate HTLV-II infection US blood donors important public health donor counselling issues HTLV-I infection adult T-cell leukaemia neurological disorder pathogenicity HTLV-II unclear